Mathieu Ferrari
Overview
Explore the profile of Mathieu Ferrari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferrari M, Parekh F, Maciocia P, Horna P, Thomas S, Sewell A, et al.
Nat Commun
. 2025 Jan;
16(1):1103.
PMID: 39880830
No abstract available.
2.
Manipadam M, Marra A, Ramsay A, Padmasri S, Gosh A, Neves M, et al.
Hematol Oncol
. 2024 Dec;
43(1):e70018.
PMID: 39655706
No abstract available.
3.
Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine D, Balasubramaniam N, et al.
Nat Med
. 2024 Nov;
31(1):137-143.
PMID: 39528665
Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely...
4.
Horna P, Weybright M, Ferrari M, Jungherz D, Peng Y, Akbar Z, et al.
Blood Cancer J
. 2024 Feb;
14(1):34.
PMID: 38424120
The diagnosis of leukemic T-cell malignancies is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. Recently developed therapeutic antibodies specific for...
5.
Ferrari M, Righi M, Baldan V, Wawrzyniecka P, Bulek A, Kinna A, et al.
Nat Commun
. 2024 Feb;
15(1):1583.
PMID: 38383515
Peripheral T cell lymphomas are typically aggressive with a poor prognosis. Unlike other hematologic malignancies, the lack of target antigens to discriminate healthy from malignant cells limits the efficacy of...
6.
Jha R, Kinna A, Hotblack A, Bughda R, Bulek A, Gannon I, et al.
ACS Chem Biol
. 2024 Jan;
19(2):308-324.
PMID: 38243811
A versatile, safe, and effective small-molecule control system is highly desirable for clinical cell therapy applications. Therefore, we developed a two-component small-molecule control system based on the disruption of protein-protein...
7.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, et al.
Mol Ther
. 2023 Dec;
32(2):556-558.
PMID: 38103549
No abstract available.
8.
Lee L, Lim W, Galas-Filipowicz D, Fung K, Taylor J, Patel D, et al.
J Immunother Cancer
. 2023 Jul;
11(6).
PMID: 37399355
Background: We used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma antigens, B-cell maturation antigen (BCMA) and transmembrane activator...
9.
Taylor J, Bulek A, Gannon I, Robson M, Kokalaki E, Grothier T, et al.
Front Immunol
. 2023 Jun;
14:1119350.
PMID: 37334382
SHP1 and SHP2 are SH2 domain-containing proteins which have inhibitory phosphatase activity when recruited to phosphorylated ITIMs and ITSMs on inhibitory immune receptors. Consequently, SHP1 and SHP2 are key proteins...
10.
Kokalaki E, Ma B, Ferrari M, Grothier T, Hazelton W, Manzoor S, et al.
Mol Ther
. 2023 Mar;
31(7):2089-2104.
PMID: 36945773
CAR T cells recognizing CD19 effectively treat relapsed and refractory B-ALL and DLBCL. However, CD19 loss is a frequent cause of relapse. Simultaneously targeting a second antigen, CD22, may decrease...